Mr. Bill Adams reports
NERVGEN PHARMA GRANTS STOCK OPTIONS
Nervgen Pharma Corp. has granted incentive stock options to the company's employees, including 505,200 to the company's officers, exercisable at a price of $3.48 per share for a period of 10 years and that vest equally every six months over a two-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan.
About Nervgen Pharma Corp.
Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. Nervgen's lead drug candidate, NVG-291, is being evaluated in a phase 1b/2a clinical trial. The company's initial target indication is spinal cord injury.
© 2024 Canjex Publishing Ltd. All rights reserved.